Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
Mol Imaging Biol. 2013 Feb;15(1):106-13. doi: 10.1007/s11307-012-0566-y.
This pilot study was performed to evaluate whether tumor uptake of (18)F-labeled 3'-deoxy-3'fluorothymidine (FLT), a proliferative radiotracer, at baseline and early during therapy, is predictive of outcome in locally advanced rectal cancer.
Fourteen patients underwent positron emission tomography (PET) with 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) and FLT before therapy and PET with FLT approximately 2 weeks after initiating neoadjuvant chemoradiotherapy. FLT and FDG uptake were evaluated qualitatively and by maximum standardized uptake value (SUV(max)). Tumor FLT and FDG uptake were correlated with disease-free survival (DFS).
Thirteen patients underwent surgery after therapy, one died before surgery with progressive disease. FDG-PET/computed tomography detected regional lymph node metastases in five and FLT-PET was positive in one. High pretherapy FDG uptake (SUV(max) ≥ 14.3), low during-therapy FLT uptake (SUV(max) < 2.2), and high percentage change in FLT uptake (≥60 %) were predictive of improved DFS (p < 0.05 for all three values).
Pretherapy FDG uptake, during-therapy FLT uptake, and percentage change in FLT uptake were equally predictive of DFS.
本初步研究旨在评估基线和治疗早期时肿瘤对（18）F 标记的 3'-去氧-3'氟胸苷（FLT）的摄取（FLT，一种增殖放射性示踪剂）是否可预测局部晚期直肠癌的治疗结果。
14 名患者在治疗前进行了正电子发射断层扫描（PET）检查，使用 2-脱氧-2-[(18)F]氟代-D-葡萄糖（FDG）和 FLT，在接受新辅助放化疗后约 2 周时进行了 FLT-PET 检查。通过最大标准化摄取值（SUV(max)）对 FLT 和 FDG 摄取进行定性和定量评估。评估肿瘤 FLT 和 FDG 摄取与无病生存率（DFS）的相关性。
13 名患者在治疗后接受了手术，1 名患者在疾病进展前死于手术。FDG-PET/计算机断层扫描（CT）在 5 名患者中检测到局部淋巴结转移，FLT-PET 在 1 名患者中呈阳性。高治疗前 FDG 摄取（SUV(max)≥14.3）、治疗期间低 FLT 摄取（SUV(max)<2.2）和 FLT 摄取百分比变化高（≥60%）与改善的 DFS 相关（所有三个值的 p<0.05）。
治疗前的 FDG 摄取、治疗期间的 FLT 摄取和 FLT 摄取百分比变化均可预测 DFS。
